|
V4836
|
LY 254155 |
135503-67-2 |
LY 254155 is a potent antifolate compound which inhibitshGARFTand binds tomFBPwithKis of 2.1±0.2 and 1.7±0.1 nM, respectively. |
|
V4840
|
LY 541850 |
852679-76-6 |
LY 541850 is a novel, potent and selective agonist of mGlu2 (human ionotropic and metabotropic glutamate) receptors expressed in non-neuronal cells. |
|
V4850
|
LY-210073 |
148291-65-0 |
LY210073 is a Leukotriene B4 (LTB4) receptor blocker (antagonist) with IC50 of 6.2 nM. |
|
V4856
|
LY-2794193 |
2173037-97-1 |
LY2794193 is a novel, highly potent and selectivemGlu3 receptoragonist withKi/ EC50of 0.927 nM / 0.47 nM; 412 nM / 47.5 nM forhmGlu3andhmGlu2, respectively. |
|
V4861
|
LY-2857785 |
1619903-54-6 |
LY2857785 is a novel, potent, selective, type I reversible and competitive ATP kinase inhibitor againstCDK9(IC5011 nM) and other transcription kinasesCDK8(IC5016 nM), andCDK7(IC50246 nM). |
|
V4858
|
LY-2922470 |
1423018-12-5 |
LY2922470 is a novel, potent, selective and orally bioavailable GPR40 (G protein-coupled receptor 40) agonist withEC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. |
|
V4884
|
LY-3295668 |
1919888-06-4 |
LY3295668 (LY-3295668; AK-01; Erbumine;AK01) is a novel, potent, orally bioavailable and highly selectiveAurora-A kinaseinhibitor with potential anticancer activity. |
|
V4865
|
LY-450108 |
376594-67-1 |
LY450108 is a potent AMPA receptor enhancer. |
|
V4885
|
LY223982 |
117423-74-2 |
LY 223982 is a novel, potent and specific BLT1 (leukotriene B4) receptor antagonist with anIC50of 13.2 nM against [3H]LTB4 binding to LTB4 receptor. |
|
V4857
|
LY2812223 |
1311385-20-2 |
LY2812223 is a novel, highly potent, functionally selectivemGlu2receptoragonist with mGlu2binding affinity (Ki) of 144 nM and 156 nM for mGlu2and mGlu3, respectively. |
|
V4859
|
LY2881835 |
1292290-38-0 |
LY2881835 is a novel, potent, selective and orally bioavailable GPR40 (G protein-coupled receptor 40) agonist. |
|
V4860
|
LY2922083 |
1309435-78-6 |
LY2922083 is a novel, potent, selective and orally bioavailable GPR40 (G protein-coupled receptor 40) agonist. |
|
V4849
|
LY2979165 |
1311385-32-6 |
LY2979165, a novel and potent mGlu2 agonist being developed as an anti-depressant drug candidate, has potential usefulness in the treatment of bipolar disorder. |
|
V4843
|
LY3000328 |
1373215-15-6 |
LY3000328 is a novel, potent and selective Cathepsin S (Cat S) inhibitor withIC50s of 7.7 and 1.67 nM for hCat S and mCat S, respectively. |
|
V4882
|
LY3020371 HCl |
1377615-44-5 |
LY3020371 HCl is a novel, potent, selective mGlu2/3 (metabotropic glutamate 2/3) receptor antagonist withKiof 5.3 and 2.5 nM, potently blocks cAMP formation withIC50of 16.2 nM. |
|
V4855
|
Ly93 |
1883528-69-5 |
Ly93 (SMS2-IN-Ly93) is a novel, potent, selective and oral bioavailablesphingomyelin synthase 2 (SMS2)inhibitor with anIC50of 91 nM, showing more than 1400-fold selectivity over sms1 |
|
V4770
|
MB-07811 (VK-2809) |
852948-13-1 |
MB-07811 (also known as prodrug of MB-07344, and VK-2809), a liver-targetedthyroid hormone receptor-β(TRB) agonist, is a novel, potent and orally bioavailable HepDirect prodrug of MB07344. |
|
V4652
|
Mc-MMAF |
863971-19-1 |
Mc-MMAF (Mafodotin; SGD-1269 or Maleimidocaproyl monomethylauristatin F) is a protective group-conjugated MMAFhaving a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. |
|
V5186
|
McN3716 (Methyl palmoxirate; NSC359682) |
69207-52-9 |
McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor. |
|
V4728
|
MEK inhibitor |
334951-92-7 |
MEK inhibitor is a MEK inhibitor (antagonist) with anti-tumor activity. |